Abiomed, Inc. (NASDAQ: ABMD) Stock Competitors & Peer Comparison
See ABMD's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ABMD and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ABMD | $381.02 | +0.00% | 17.2B | 65.36 | $5.83 | N/A |
| ABT | $108.62 | +0.75% | 188B | 20.86 | $5.21 | +2.28% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $345.81 | +2.00% | 132.5B | 25.82 | $13.39 | +1.01% |
| MDT | $89.41 | +2.58% | 114.4B | 16.17 | $5.53 | +3.20% |
| BSX | $50.46 | +2.33% | 75B | 16.28 | $3.10 | N/A |
| EW | $92.03 | +2.57% | 53B | 34.09 | $2.70 | N/A |
| DXCM | $87.65 | +3.42% | 33.1B | 37.62 | $2.33 | N/A |
| RMD | $220.05 | +3.83% | 31.9B | 20.44 | $10.77 | +1.09% |
| PHG | $26.94 | +0.79% | 26.3B | 15.39 | $1.75 | +3.68% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
ABMD vs ABT Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ABT has a market cap of 188B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while ABT trades at $108.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ABT's P/E ratio is 20.86. In terms of profitability, ABMD's ROE is +0.10%, compared to ABT's ROE of +0.11%. Regarding short-term risk, ABMD is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
ABMD vs BSX-PA Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ABMD's ROE is +0.10%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, ABMD is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check BSX-PA's competition here
Stryker Corporation (NYSE: SYK)
ABMD vs SYK Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, SYK has a market cap of 132.5B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while SYK trades at $345.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas SYK's P/E ratio is 25.82. In terms of profitability, ABMD's ROE is +0.10%, compared to SYK's ROE of +0.16%. Regarding short-term risk, ABMD is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check SYK's competition here
Medtronic plc (NYSE: MDT)
ABMD vs MDT Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, MDT has a market cap of 114.4B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while MDT trades at $89.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas MDT's P/E ratio is 16.17. In terms of profitability, ABMD's ROE is +0.10%, compared to MDT's ROE of +0.10%. Regarding short-term risk, ABMD is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
ABMD vs BSX Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, BSX has a market cap of 75B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while BSX trades at $50.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas BSX's P/E ratio is 16.28. In terms of profitability, ABMD's ROE is +0.10%, compared to BSX's ROE of +0.15%. Regarding short-term risk, ABMD is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
ABMD vs EW Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, EW has a market cap of 53B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while EW trades at $92.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas EW's P/E ratio is 34.09. In terms of profitability, ABMD's ROE is +0.10%, compared to EW's ROE of +0.10%. Regarding short-term risk, ABMD is less volatile compared to EW. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
ABMD vs DXCM Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, DXCM has a market cap of 33.1B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while DXCM trades at $87.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas DXCM's P/E ratio is 37.62. In terms of profitability, ABMD's ROE is +0.10%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, ABMD is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check DXCM's competition here
ResMed Inc. (NYSE: RMD)
ABMD vs RMD Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, RMD has a market cap of 31.9B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while RMD trades at $220.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas RMD's P/E ratio is 20.44. In terms of profitability, ABMD's ROE is +0.10%, compared to RMD's ROE of +0.24%. Regarding short-term risk, ABMD is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check RMD's competition here
Koninklijke Philips N.V. (NYSE: PHG)
ABMD vs PHG Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, PHG has a market cap of 26.3B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while PHG trades at $26.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas PHG's P/E ratio is 15.39. In terms of profitability, ABMD's ROE is +0.10%, compared to PHG's ROE of +0.10%. Regarding short-term risk, ABMD is less volatile compared to PHG. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
ABMD vs ZBH Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ZBH has a market cap of 18.9B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while ZBH trades at $97.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ZBH's P/E ratio is 11.53. In terms of profitability, ABMD's ROE is +0.10%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, ABMD is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check ZBH's competition here
Penumbra, Inc. (NYSE: PEN)
ABMD vs PEN Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, PEN has a market cap of 12.8B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while PEN trades at $325.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas PEN's P/E ratio is 85.11. In terms of profitability, ABMD's ROE is +0.10%, compared to PEN's ROE of +0.11%. Regarding short-term risk, ABMD is less volatile compared to PEN. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check PEN's competition here
Smith & Nephew plc (NYSE: SNN)
ABMD vs SNN Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, SNN has a market cap of 12.6B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while SNN trades at $30.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas SNN's P/E ratio is 14.16. In terms of profitability, ABMD's ROE is +0.10%, compared to SNN's ROE of +0.12%. Regarding short-term risk, ABMD is less volatile compared to SNN. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check SNN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
ABMD vs SWAV Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ABMD's ROE is +0.10%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ABMD is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for ABMD.Check SWAV's competition here
Align Technology, Inc. (NASDAQ: ALGN)
ABMD vs ALGN Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ALGN has a market cap of 12.4B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while ALGN trades at $176.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ALGN's P/E ratio is 15.83. In terms of profitability, ABMD's ROE is +0.10%, compared to ALGN's ROE of +0.14%. Regarding short-term risk, ABMD is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check ALGN's competition here
Globus Medical, Inc. (NYSE: GMED)
ABMD vs GMED Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, GMED has a market cap of 11.6B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while GMED trades at $86.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas GMED's P/E ratio is 19.40. In terms of profitability, ABMD's ROE is +0.10%, compared to GMED's ROE of +0.12%. Regarding short-term risk, ABMD is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
ABMD vs GKOS Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, GKOS has a market cap of 10.7B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while GKOS trades at $181.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas GKOS's P/E ratio is -210.81. In terms of profitability, ABMD's ROE is +0.10%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, ABMD is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check GKOS's competition here
Insulet Corp. (NASDAQ: PODD)
ABMD vs PODD Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, PODD has a market cap of 9.9B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while PODD trades at $142.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas PODD's P/E ratio is 24.34. In terms of profitability, ABMD's ROE is +0.10%, compared to PODD's ROE of +0.27%. Regarding short-term risk, ABMD is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
ABMD vs BIO Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, BIO has a market cap of 9.6B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while BIO trades at $354.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas BIO's P/E ratio is 38.24. In terms of profitability, ABMD's ROE is +0.10%, compared to BIO's ROE of +0.03%. Regarding short-term risk, ABMD is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check BIO's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
ABMD vs BIO-B Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, BIO-B has a market cap of 9.5B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while BIO-B trades at $349.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas BIO-B's P/E ratio is 103.54. In terms of profitability, ABMD's ROE is +0.10%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, ABMD is less volatile compared to BIO-B. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check BIO-B's competition here
Masimo Corporation (NASDAQ: MASI)
ABMD vs MASI Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas MASI's P/E ratio is 44.43. In terms of profitability, ABMD's ROE is +0.10%, compared to MASI's ROE of +0.09%. Regarding short-term risk, ABMD is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for ABMD.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
ABMD vs BRKR Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, BRKR has a market cap of 8.6B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while BRKR trades at $56.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas BRKR's P/E ratio is 28.30. In terms of profitability, ABMD's ROE is +0.10%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, ABMD is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check BRKR's competition here
Inari Medical, Inc. (NASDAQ: NARI)
ABMD vs NARI Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas NARI's P/E ratio is -59.24. In terms of profitability, ABMD's ROE is +0.10%, compared to NARI's ROE of -0.00%. Regarding short-term risk, ABMD is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for ABMD.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
ABMD vs ITGR Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ITGR has a market cap of 4.2B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while ITGR trades at $125.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ITGR's P/E ratio is 19.70. In terms of profitability, ABMD's ROE is +0.10%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, ABMD is less volatile compared to ITGR. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check ITGR's competition here
LivaNova PLC (NASDAQ: LIVN)
ABMD vs LIVN Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while LIVN trades at $76.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas LIVN's P/E ratio is 18.17. In terms of profitability, ABMD's ROE is +0.10%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, ABMD is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check LIVN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
ABMD vs IRTC Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, IRTC has a market cap of 4.1B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while IRTC trades at $124.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas IRTC's P/E ratio is -194.97. In terms of profitability, ABMD's ROE is +0.10%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, ABMD is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check IRTC's competition here
Haemonetics Corporation (NYSE: HAE)
ABMD vs HAE Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, HAE has a market cap of 3.9B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while HAE trades at $86.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas HAE's P/E ratio is 17.29. In terms of profitability, ABMD's ROE is +0.10%, compared to HAE's ROE of +0.11%. Regarding short-term risk, ABMD is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check HAE's competition here
Axonics, Inc. (NASDAQ: AXNX)
ABMD vs AXNX Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ABMD's ROE is +0.10%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ABMD is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for ABMD.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
ABMD vs TMDX Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, TMDX has a market cap of 3.1B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while TMDX trades at $88.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas TMDX's P/E ratio is 44.88. In terms of profitability, ABMD's ROE is +0.10%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, ABMD is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
ABMD vs AXGN Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, AXGN has a market cap of 2.6B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while AXGN trades at $48.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas AXGN's P/E ratio is 126.89. In terms of profitability, ABMD's ROE is +0.10%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, ABMD is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check AXGN's competition here
Butterfly Network, Inc. (NYSE: BFLY)
ABMD vs BFLY Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, BFLY has a market cap of 2.6B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while BFLY trades at $9.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas BFLY's P/E ratio is -40.42. In terms of profitability, ABMD's ROE is +0.10%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, ABMD is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check BFLY's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
ABMD vs UFPT Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, UFPT has a market cap of 2.5B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while UFPT trades at $325.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas UFPT's P/E ratio is 33.20. In terms of profitability, ABMD's ROE is +0.10%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, ABMD is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check UFPT's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
ABMD vs ESTA Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while ESTA trades at $75.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ESTA's P/E ratio is -59.57. In terms of profitability, ABMD's ROE is +0.10%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, ABMD is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check ESTA's competition here
NuVasive, Inc. (NASDAQ: NUVA)
ABMD vs NUVA Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ABMD's ROE is +0.10%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ABMD is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check NUVA's competition here
Novocure Ltd (NASDAQ: NVCR)
ABMD vs NVCR Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, NVCR has a market cap of 2B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while NVCR trades at $17.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas NVCR's P/E ratio is -11.31. In terms of profitability, ABMD's ROE is +0.10%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, ABMD is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check NVCR's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
ABMD vs INSP Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, INSP has a market cap of 1.7B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while INSP trades at $59.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas INSP's P/E ratio is 26.31. In terms of profitability, ABMD's ROE is +0.10%, compared to INSP's ROE of +0.18%. Regarding short-term risk, ABMD is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check INSP's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
ABMD vs TNDM Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, TNDM has a market cap of 1.6B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while TNDM trades at $22.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas TNDM's P/E ratio is -20.74. In terms of profitability, ABMD's ROE is +0.10%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, ABMD is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check TNDM's competition here
CONMED Corporation (NYSE: CNMD)
ABMD vs CNMD Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while CNMD trades at $49.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas CNMD's P/E ratio is 10.87. In terms of profitability, ABMD's ROE is +0.10%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, ABMD is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check CNMD's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
ABMD vs ATEC Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ATEC has a market cap of 1.4B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while ATEC trades at $9.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ATEC's P/E ratio is -155.17. In terms of profitability, ABMD's ROE is +0.10%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, ABMD is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check ATEC's competition here
Enovis Corporation (NYSE: ENOV)
ABMD vs ENOV Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ENOV has a market cap of 1.4B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while ENOV trades at $24.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ENOV's P/E ratio is 6.96. In terms of profitability, ABMD's ROE is +0.10%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, ABMD is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check ENOV's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
ABMD vs IART Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while IART trades at $17.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas IART's P/E ratio is 7.23. In terms of profitability, ABMD's ROE is +0.10%, compared to IART's ROE of -0.01%. Regarding short-term risk, ABMD is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check IART's competition here
Artivion, Inc. (NYSE: AORT)
ABMD vs AORT Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while AORT trades at $26.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas AORT's P/E ratio is 45.28. In terms of profitability, ABMD's ROE is +0.10%, compared to AORT's ROE of -0.01%. Regarding short-term risk, ABMD is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check AORT's competition here
Heska Corporation (NASDAQ: HSKA)
ABMD vs HSKA Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ABMD's ROE is +0.10%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ABMD is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for ABMD.Check HSKA's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
ABMD vs PRCT Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while PRCT trades at $21.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas PRCT's P/E ratio is -11.19. In terms of profitability, ABMD's ROE is +0.10%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, ABMD is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check PRCT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
ABMD vs AVNS Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas AVNS's P/E ratio is 27.77. In terms of profitability, ABMD's ROE is +0.10%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, ABMD is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for ABMD.Check AVNS's competition here
IRadimed Corporation (NASDAQ: IRMD)
ABMD vs IRMD Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while IRMD trades at $90.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas IRMD's P/E ratio is 45.36. In terms of profitability, ABMD's ROE is +0.10%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, ABMD is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check IRMD's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
ABMD vs LMRI Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while LMRI trades at $11.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas LMRI's P/E ratio is -22.84. In terms of profitability, ABMD's ROE is +0.10%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, ABMD is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check LMRI's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
ABMD vs SILK Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas SILK's P/E ratio is -18.96. In terms of profitability, ABMD's ROE is +0.10%, compared to SILK's ROE of -0.35%. Regarding short-term risk, ABMD is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for ABMD.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
ABMD vs FNA Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas FNA's P/E ratio is -19.83. In terms of profitability, ABMD's ROE is +0.10%, compared to FNA's ROE of -0.35%. Regarding short-term risk, ABMD is less volatile compared to FNA. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check FNA's competition here
Bioventus Inc. (NASDAQ: BVS)
ABMD vs BVS Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, BVS has a market cap of 945.8M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while BVS trades at $13.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas BVS's P/E ratio is 18.37. In terms of profitability, ABMD's ROE is +0.10%, compared to BVS's ROE of +0.28%. Regarding short-term risk, ABMD is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check BVS's competition here
InMode Ltd. (NASDAQ: INMD)
ABMD vs INMD Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, INMD has a market cap of 873.1M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while INMD trades at $15.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas INMD's P/E ratio is 10.55. In terms of profitability, ABMD's ROE is +0.10%, compared to INMD's ROE of +0.12%. Regarding short-term risk, ABMD is less volatile compared to INMD. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check INMD's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
ABMD vs AVR Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, AVR has a market cap of 866.3M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while AVR trades at $8.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas AVR's P/E ratio is -4.00. In terms of profitability, ABMD's ROE is +0.10%, compared to AVR's ROE of -1.24%. Regarding short-term risk, ABMD is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check AVR's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
ABMD vs CSII Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas CSII's P/E ratio is -20.83. In terms of profitability, ABMD's ROE is +0.10%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ABMD is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for ABMD.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
ABMD vs SIBN Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, SIBN has a market cap of 835.5M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while SIBN trades at $18.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas SIBN's P/E ratio is -55.41. In terms of profitability, ABMD's ROE is +0.10%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, ABMD is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check SIBN's competition here
Varex Imaging Corporation (NASDAQ: VREX)
ABMD vs VREX Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, VREX has a market cap of 777.2M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while VREX trades at $18.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas VREX's P/E ratio is 19.43. In terms of profitability, ABMD's ROE is +0.10%, compared to VREX's ROE of +0.05%. Regarding short-term risk, ABMD is less volatile compared to VREX. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check VREX's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
ABMD vs SSII Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, SSII has a market cap of 746.5M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while SSII trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas SSII's P/E ratio is -72.75. In terms of profitability, ABMD's ROE is +0.10%, compared to SSII's ROE of -0.23%. Regarding short-term risk, ABMD is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check SSII's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
ABMD vs BBNX Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, BBNX has a market cap of 737.8M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while BBNX trades at $16.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas BBNX's P/E ratio is -10.86. In terms of profitability, ABMD's ROE is +0.10%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, ABMD is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check BBNX's competition here
CeriBell, Inc. (NASDAQ: CBLL)
ABMD vs CBLL Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, CBLL has a market cap of 732.3M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while CBLL trades at $19.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas CBLL's P/E ratio is -11.84. In terms of profitability, ABMD's ROE is +0.10%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, ABMD is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check CBLL's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
ABMD vs AHCO Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, AHCO has a market cap of 710.2M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while AHCO trades at $5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas AHCO's P/E ratio is 10.65. In terms of profitability, ABMD's ROE is +0.10%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, ABMD is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check AHCO's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
ABMD vs TCMD Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, TCMD has a market cap of 657.3M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while TCMD trades at $29.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas TCMD's P/E ratio is 33.11. In terms of profitability, ABMD's ROE is +0.10%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, ABMD is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check TCMD's competition here
Surmodics, Inc. (NASDAQ: SRDX)
ABMD vs SRDX Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas SRDX's P/E ratio is -34.66. In terms of profitability, ABMD's ROE is +0.10%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, ABMD is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for ABMD.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
ABMD vs CTKB Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, CTKB has a market cap of 601.8M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while CTKB trades at $4.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas CTKB's P/E ratio is -24.69. In terms of profitability, ABMD's ROE is +0.10%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, ABMD is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check CTKB's competition here
BrainsWay Ltd. (NASDAQ: BWAY)
ABMD vs BWAY Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, BWAY has a market cap of 600.9M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while BWAY trades at $15.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas BWAY's P/E ratio is 38.92. In terms of profitability, ABMD's ROE is +0.10%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, ABMD is less volatile compared to BWAY. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check BWAY's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
ABMD vs KIDS Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, KIDS has a market cap of 597.9M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while KIDS trades at $23.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas KIDS's P/E ratio is -19.73. In terms of profitability, ABMD's ROE is +0.10%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, ABMD is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check KIDS's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
ABMD vs APEN Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas APEN's P/E ratio is -9.43. In terms of profitability, ABMD's ROE is +0.10%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ABMD is less volatile compared to APEN. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check APEN's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
ABMD vs DCTH Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, DCTH has a market cap of 575.5M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while DCTH trades at $16.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas DCTH's P/E ratio is 1667.00. In terms of profitability, ABMD's ROE is +0.10%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, ABMD is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
ABMD vs ZIMV Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, ABMD's ROE is +0.10%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, ABMD is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for ABMD.Check ZIMV's competition here
Cerus Corporation (NASDAQ: CERS)
ABMD vs CERS Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, CERS has a market cap of 507.8M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while CERS trades at $2.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas CERS's P/E ratio is -50.30. In terms of profitability, ABMD's ROE is +0.10%, compared to CERS's ROE of -0.10%. Regarding short-term risk, ABMD is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
ABMD vs NPCE Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, NPCE has a market cap of 507.3M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while NPCE trades at $14.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas NPCE's P/E ratio is -25.66. In terms of profitability, ABMD's ROE is +0.10%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, ABMD is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check NPCE's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
ABMD vs CLPT Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, CLPT has a market cap of 436.9M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while CLPT trades at $14.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas CLPT's P/E ratio is -12.35. In terms of profitability, ABMD's ROE is +0.10%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, ABMD is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check CLPT's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
ABMD vs SGHT Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, SGHT has a market cap of 419M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while SGHT trades at $7.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas SGHT's P/E ratio is -13.75. In terms of profitability, ABMD's ROE is +0.10%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, ABMD is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check SGHT's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
ABMD vs OFIX Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, OFIX has a market cap of 414.7M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while OFIX trades at $10.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas OFIX's P/E ratio is -13.40. In terms of profitability, ABMD's ROE is +0.10%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, ABMD is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check OFIX's competition here
Picard Medical, Inc. (AMEX: PMI)
ABMD vs PMI Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, PMI has a market cap of 375.9M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while PMI trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas PMI's P/E ratio is -3.05. In terms of profitability, ABMD's ROE is +0.10%, compared to PMI's ROE of +4.99%. Regarding short-term risk, ABMD is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check PMI's competition here
Carlsmed, Inc. (NASDAQ: CARL)
ABMD vs CARL Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, CARL has a market cap of 373.2M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while CARL trades at $13.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas CARL's P/E ratio is -9.60. In terms of profitability, ABMD's ROE is +0.10%, compared to CARL's ROE of -0.38%. Regarding short-term risk, ABMD is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check CARL's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
ABMD vs PACB Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, PACB has a market cap of 357.2M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while PACB trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas PACB's P/E ratio is -2.80. In terms of profitability, ABMD's ROE is +0.10%, compared to PACB's ROE of -49.62%. Regarding short-term risk, ABMD is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check PACB's competition here
Electromed, Inc. (AMEX: ELMD)
ABMD vs ELMD Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ELMD has a market cap of 353.1M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while ELMD trades at $42.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ELMD's P/E ratio is 36.44. In terms of profitability, ABMD's ROE is +0.10%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, ABMD is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check ELMD's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
ABMD vs CATX Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, CATX has a market cap of 342.1M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while CATX trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas CATX's P/E ratio is -2.13. In terms of profitability, ABMD's ROE is +0.10%, compared to CATX's ROE of -0.42%. Regarding short-term risk, ABMD is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check CATX's competition here
CapsoVision, Inc. (NASDAQ: CV)
ABMD vs CV Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, CV has a market cap of 333.8M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while CV trades at $6.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas CV's P/E ratio is -2.67. In terms of profitability, ABMD's ROE is +0.10%, compared to CV's ROE of +1.27%. Regarding short-term risk, ABMD is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check CV's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
ABMD vs SENS Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, SENS has a market cap of 315.1M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while SENS trades at $7.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas SENS's P/E ratio is -3.77. In terms of profitability, ABMD's ROE is +0.10%, compared to SENS's ROE of -1.66%. Regarding short-term risk, ABMD is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check SENS's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
ABMD vs SMLR Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas SMLR's P/E ratio is 3.92. In terms of profitability, ABMD's ROE is +0.10%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, ABMD is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for ABMD.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
ABMD vs TMCI Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, TMCI has a market cap of 303M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while TMCI trades at $4.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas TMCI's P/E ratio is -4.97. In terms of profitability, ABMD's ROE is +0.10%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, ABMD is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check TMCI's competition here
Anika Therapeutics, Inc. (NASDAQ: ANIK)
ABMD vs ANIK Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ANIK has a market cap of 286.7M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while ANIK trades at $20.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ANIK's P/E ratio is 43.71. In terms of profitability, ABMD's ROE is +0.10%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, ABMD is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check ANIK's competition here
RxSight, Inc. (NASDAQ: RXST)
ABMD vs RXST Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, RXST has a market cap of 272M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while RXST trades at $6.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas RXST's P/E ratio is -7.06. In terms of profitability, ABMD's ROE is +0.10%, compared to RXST's ROE of -0.17%. Regarding short-term risk, ABMD is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check RXST's competition here
Profound Medical Corp. (NASDAQ: PROF)
ABMD vs PROF Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, PROF has a market cap of 266.7M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while PROF trades at $7.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas PROF's P/E ratio is -5.92. In terms of profitability, ABMD's ROE is +0.10%, compared to PROF's ROE of -0.56%. Regarding short-term risk, ABMD is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check PROF's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
ABMD vs MGRM Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas MGRM's P/E ratio is -12.00. In terms of profitability, ABMD's ROE is +0.10%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, ABMD is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for ABMD.Check MGRM's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
ABMD vs FOCL Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, FOCL has a market cap of 227.9M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while FOCL trades at $6.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas FOCL's P/E ratio is -7.82. In terms of profitability, ABMD's ROE is +0.10%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, ABMD is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check FOCL's competition here
Nevro Corp. (NYSE: NVRO)
ABMD vs NVRO Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ABMD's ROE is +0.10%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ABMD is less volatile compared to NVRO. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check NVRO's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
ABMD vs TLSI Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, TLSI has a market cap of 211.5M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while TLSI trades at $5.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas TLSI's P/E ratio is -3.32. In terms of profitability, ABMD's ROE is +0.10%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, ABMD is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check TLSI's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
ABMD vs BSGM Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas BSGM's P/E ratio is -5.81. In terms of profitability, ABMD's ROE is +0.10%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, ABMD is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check BSGM's competition here
Avita Medical Inc. (NASDAQ: RCEL)
ABMD vs RCEL Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, RCEL has a market cap of 188.8M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while RCEL trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas RCEL's P/E ratio is -4.84. In terms of profitability, ABMD's ROE is +0.10%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, ABMD is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check RCEL's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
ABMD vs MDGS Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ABMD's ROE is +0.10%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ABMD is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check MDGS's competition here
Inogen, Inc. (NASDAQ: INGN)
ABMD vs INGN Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, INGN has a market cap of 163M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while INGN trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas INGN's P/E ratio is -6.62. In terms of profitability, ABMD's ROE is +0.10%, compared to INGN's ROE of -0.13%. Regarding short-term risk, ABMD is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check INGN's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
ABMD vs QIPT Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas QIPT's P/E ratio is -15.87. In terms of profitability, ABMD's ROE is +0.10%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, ABMD is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for ABMD.Check QIPT's competition here
Neuronetics, Inc. (NASDAQ: STIM)
ABMD vs STIM Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, STIM has a market cap of 151M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while STIM trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas STIM's P/E ratio is -4.02. In terms of profitability, ABMD's ROE is +0.10%, compared to STIM's ROE of -1.65%. Regarding short-term risk, ABMD is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check STIM's competition here
Quanterix Corporation (NASDAQ: QTRX)
ABMD vs QTRX Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, QTRX has a market cap of 114M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while QTRX trades at $2.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas QTRX's P/E ratio is -1.51. In terms of profitability, ABMD's ROE is +0.10%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, ABMD is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check QTRX's competition here
iCAD, Inc. (NASDAQ: ICAD)
ABMD vs ICAD Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas ICAD's P/E ratio is -20.37. In terms of profitability, ABMD's ROE is +0.10%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, ABMD is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for ABMD.Check ICAD's competition here
Solana Company (NASDAQ: HSDT)
ABMD vs HSDT Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, HSDT has a market cap of 99.3M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while HSDT trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas HSDT's P/E ratio is -0.02. In terms of profitability, ABMD's ROE is +0.10%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, ABMD is less volatile compared to HSDT. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check HSDT's competition here
Owlet, Inc. (NYSE: OWLT)
ABMD vs OWLT Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, OWLT has a market cap of 98.4M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while OWLT trades at $5.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas OWLT's P/E ratio is -38.86. In terms of profitability, ABMD's ROE is +0.10%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, ABMD is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check OWLT's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
ABMD vs LUCD Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, LUCD has a market cap of 98.3M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while LUCD trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas LUCD's P/E ratio is -2.60. In terms of profitability, ABMD's ROE is +0.10%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, ABMD is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check LUCD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
ABMD vs HJLI Comparison August 2026
Abiomed, Inc. (NASDAQ: ABMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABMD stands at 17.2B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, ABMD is priced at $381.02 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABMD currently has a P/E ratio of 65.36, whereas HJLI's P/E ratio is N/A. In terms of profitability, ABMD's ROE is +0.10%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, ABMD is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for ABMD.Check HJLI's competition here